Which has stronger valuation and earnings, GRFS or GMAB?

Genmab A/S has lower revenue, but higher earnings than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.63 $454.82M $0.19 41.47 Genmab A/S $3.72B 5.77 $963M $1.27 27.09

Is GRFS or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 14.89% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Genmab A/S 19.08% 14.89% 7.73%

Which has better earnings & valuation, BBIO or GRFS?

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 29.36 -$724.93M -$3.57 N/A Grifols $8.51B 0.63 $454.82M $0.19 41.47

Which has higher valuation & earnings, ASND or GRFS?

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 20.76 -$258M $12.89 21.03 Grifols $8.51B 0.63 $454.82M $0.19 41.47

Which has stronger valuation & earnings, EXEL or GRFS?

Exelixis has higher earnings, but lower revenue than Grifols. Exelixis is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.31 $782.57M $3.18 18.59 Grifols $8.51B 0.63 $454.82M $0.19 41.47

Is EXEL or GRFS more profitable?

Exelixis has a net margin of 35.33% compared to Grifols' net margin of 5.54%. Exelixis' return on equity of 42.17% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Grifols 5.54% 6.21% 2.39%

Grifols (GRFS) Competitors

$7.88 +0.05 (+0.64%)

As of 04:00 PM Eastern

Compare

GRFS vs. GMAB, BBIO, ASND, EXEL, and ARWR

Should you buy Grifols stock or one of its competitors? Grifols's main competitors and comparable companies include Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Grifols compare to Genmab A/S?

Grifols (NASDAQ:GRFS) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Genmab A/S has a net margin of 19.08% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 14.89% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Genmab A/S	19.08%	14.89%	7.73%

In the previous week, Genmab A/S's average media sentiment score of 1.05 beat Grifols' score of 0.00 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Grifols	Neutral
Genmab A/S	Positive

Genmab A/S has lower revenue, but higher earnings than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.63	$454.82M	$0.19	41.47
Genmab A/S	$3.72B	5.77	$963M	$1.27	27.09

Grifols has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Grifols currently has a consensus target price of $10.00, suggesting a potential upside of 26.90%. Genmab A/S has a consensus target price of $39.50, suggesting a potential upside of 14.79%. Given Grifols' higher probable upside, analysts clearly believe Grifols is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Genmab A/S beats Grifols on 13 of the 16 factors compared between the two stocks.

How does Grifols compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Grifols has a net margin of 5.54% compared to BridgeBio Pharma's net margin of -97.03%. Grifols' return on equity of 6.21% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Grifols	5.54%	6.21%	2.39%

BridgeBio Pharma presently has a consensus price target of $101.53, suggesting a potential upside of 34.63%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 26.90%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe BridgeBio Pharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, BridgeBio Pharma had 18 more articles in the media than Grifols. MarketBeat recorded 18 mentions for BridgeBio Pharma and 0 mentions for Grifols. BridgeBio Pharma's average media sentiment score of 1.01 beat Grifols' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
BridgeBio Pharma	Positive
Grifols	Neutral

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	29.36	-$724.93M	-$3.57	N/A
Grifols	$8.51B	0.63	$454.82M	$0.19	41.47

Summary

BridgeBio Pharma beats Grifols on 9 of the 16 factors compared between the two stocks.

How does Grifols compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Ascendis Pharma A/S currently has a consensus target price of $310.05, suggesting a potential upside of 14.36%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 26.90%. Given Grifols' higher possible upside, analysts clearly believe Grifols is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ascendis Pharma A/S has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.76	-$258M	$12.89	21.03
Grifols	$8.51B	0.63	$454.82M	$0.19	41.47

Ascendis Pharma A/S has a net margin of 70.99% compared to Grifols' net margin of 5.54%. Ascendis Pharma A/S's return on equity of 32.54% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Grifols	5.54%	6.21%	2.39%

In the previous week, Ascendis Pharma A/S had 41 more articles in the media than Grifols. MarketBeat recorded 41 mentions for Ascendis Pharma A/S and 0 mentions for Grifols. Ascendis Pharma A/S's average media sentiment score of 0.49 beat Grifols' score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Ascendis Pharma A/S	Neutral
Grifols	Neutral

Summary

Ascendis Pharma A/S beats Grifols on 10 of the 15 factors compared between the two stocks.

How does Grifols compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Exelixis has higher earnings, but lower revenue than Grifols. Exelixis is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.31	$782.57M	$3.18	18.59
Grifols	$8.51B	0.63	$454.82M	$0.19	41.47

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Grifols' net margin of 5.54%. Exelixis' return on equity of 42.17% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Grifols	5.54%	6.21%	2.39%

Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, Exelixis had 28 more articles in the media than Grifols. MarketBeat recorded 28 mentions for Exelixis and 0 mentions for Grifols. Exelixis' average media sentiment score of 0.83 beat Grifols' score of 0.00 indicating that Exelixis is being referred to more favorably in the media.

Company	Overall Sentiment
Exelixis	Positive
Grifols	Neutral

Exelixis currently has a consensus price target of $50.07, indicating a potential downside of 15.33%. Grifols has a consensus price target of $10.00, indicating a potential upside of 26.90%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Exelixis beats Grifols on 13 of the 17 factors compared between the two stocks.

How does Grifols compare to Arrowhead Pharmaceuticals?

Grifols (NASDAQ:GRFS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Grifols has a net margin of 5.54% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Grifols' return on equity of 6.21% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, Arrowhead Pharmaceuticals had 27 more articles in the media than Grifols. MarketBeat recorded 27 mentions for Arrowhead Pharmaceuticals and 0 mentions for Grifols. Arrowhead Pharmaceuticals' average media sentiment score of 0.56 beat Grifols' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Grifols	Neutral
Arrowhead Pharmaceuticals	Positive

Grifols has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Grifols presently has a consensus target price of $10.00, indicating a potential upside of 26.90%. Arrowhead Pharmaceuticals has a consensus target price of $98.42, indicating a potential upside of 13.79%. Given Grifols' higher probable upside, analysts clearly believe Grifols is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Grifols has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.63	$454.82M	$0.19	41.47
Arrowhead Pharmaceuticals	$669.50M	18.20	-$1.63M	-$2.25	N/A

Summary

Grifols and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRFS vs. The Competition

Export

Metric	Grifols	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.36B	$4.01B	$7.24B	$12.90B
Dividend Yield	1.11%	3.61%	2.53%	8.56%
P/E Ratio	41.47	12.69	273.57	25.42
Price / Sales	0.63	1,359.79	675.05	123.41
Price / Cash	5.46	105.29	76.98	52.08
Price / Book	0.58	16.27	12.91	6.15
Net Income	$454.82M	-$22.72M	$3.47B	$349.01M
7 Day Performance	0.77%	-1.70%	-0.46%	-1.48%
1 Month Performance	0.25%	10.77%	6.40%	2.46%
1 Year Performance	-17.83%	53.15%	24.88%	15.76%

Grifols Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRFS Grifols	4.0398 of 5 stars	$7.88 +0.6%	$10.00 +26.9%	-19.1%	$5.36B	$8.51B	41.47	25,247
GMAB Genmab A/S	3.8333 of 5 stars	$33.88 +2.6%	$39.50 +16.6%	+32.2%	$21.10B	$3.72B	26.65	3,029	Positive News Analyst Upgrade
BBIO BridgeBio Pharma	3.417 of 5 stars	$82.08 +1.2%	$100.79 +22.8%	+53.0%	$15.98B	$502.08M	N/A	400	Positive News Analyst Forecast
ASND Ascendis Pharma A/S	4.269 of 5 stars	$255.15 +1.3%	$300.33 +17.7%	+34.2%	$15.96B	$814.57M	19.85	1,189	News Coverage Positive News Analyst Forecast Analyst Revision
EXEL Exelixis	2.8976 of 5 stars	$55.45 +1.7%	$50.07 -9.7%	+57.4%	$13.70B	$2.32B	17.39	1,077	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRFS) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grifols (GRFS) Competitors

GRFS vs. GMAB, BBIO, ASND, EXEL, and ARWR

How does Grifols compare to Genmab A/S?

Summary

How does Grifols compare to BridgeBio Pharma?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Summary

How does Grifols compare to Exelixis?

Summary

How does Grifols compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grifols (GRFS) Competitors

GRFS vs. GMAB, BBIO, ASND, EXEL, and ARWR

How does Grifols compare to Genmab A/S?

Is GRFS or GMAB more profitable?

Does the media prefer GRFS or GMAB?

Which has stronger valuation and earnings, GRFS or GMAB?

Which has more risk & volatility, GRFS or GMAB?

Do insiders & institutionals hold more shares of GRFS or GMAB?

Do analysts prefer GRFS or GMAB?

Summary

How does Grifols compare to BridgeBio Pharma?

Is BBIO or GRFS more profitable?

Do analysts prefer BBIO or GRFS?

Does the media prefer BBIO or GRFS?

Which has more volatility & risk, BBIO or GRFS?

Do institutionals and insiders hold more shares of BBIO or GRFS?

Which has better earnings & valuation, BBIO or GRFS?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Do analysts prefer ASND or GRFS?

Which has more volatility & risk, ASND or GRFS?

Which has higher valuation & earnings, ASND or GRFS?

Is ASND or GRFS more profitable?

Does the media refer more to ASND or GRFS?

Summary

How does Grifols compare to Exelixis?

Which has stronger valuation & earnings, EXEL or GRFS?

Do insiders & institutionals believe in EXEL or GRFS?

Is EXEL or GRFS more profitable?

Which has more risk and volatility, EXEL or GRFS?

Does the media favor EXEL or GRFS?

Do analysts recommend EXEL or GRFS?

Summary

How does Grifols compare to Arrowhead Pharmaceuticals?

Do insiders and institutionals believe in GRFS or ARWR?

Is GRFS or ARWR more profitable?

Does the media refer more to GRFS or ARWR?

Which has more volatility and risk, GRFS or ARWR?

Do analysts recommend GRFS or ARWR?

Which has better earnings and valuation, GRFS or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools